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Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a disorder characterized by fibrofatty replace-
ment of cardiac myocytes that typically manifests in the right ventricle. It is inherited as an autosomal dominant disease
with reduced penetrance, although autosomal recessive forms of the disease also occur. We identified four probands with
ARVD/C caused by mutations in DSG2, which encodes desmoglein-2, a component of the cardiac desmosome. No
association between mutations in this gene and human disease has been reported elsewhere. One of these probands has
compound-heterozygous mutations in DSG2, and the remaining three have isolated heterozygous missense mutations,
each disrupting known functional components of desmoglein-2. We report that mutations in DSG2 contribute to the
development of ARVD/C.
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Arrhythmogenic right ventricular dysplasia/cardiomyop-
athy (ARVD/C [MIM #107970]) is a heritable form of car-
diomyopathy characterized by right-ventricular dysfunc-
tion and life-threatening ventricular arrhythmias. The di-
agnosis is made on the basis of criteria proposed by an
expert consensus panel in 1994.1 Both dominant and re-
cessive forms of inheritance occur.2,3 Mutations in genes
encoding several components of the cardiac desmosome
have been associated with ARVD/C. This was first recog-
nized in the autosomal recessive condition Naxos syn-
drome (MIM #601214), in which affected individuals de-
velop right-ventricular cardiomyopathy, palmoplantar
keratoderma, and woolly hair due to homozygous muta-
tions in the gene encoding junctional plakoglobin (JUP).3,4
Similarly, recessive mutations in DSP encoding desmo-
plakin have been described in Carvajal syndrome (MIM
#605676), which consists of palmoplantar keratoderma,
woolly hair, and arrhythmogenic cardiomyopathy.5 Dja-
bali and colleagues reported additional locus heteroge-
neity for Naxos syndrome and described exclusion of DSP,
JUP, and several other components of the desmosome in
two families with Naxos syndrome.6
Dominantly inherited ARVD/C in a single family was
first shown to be caused by desmoplakin (DSP) mutations
that are predicted to disrupt binding of desmoplakin to
plakoglobin.2 More recently, mutations in DSP were re-
ported in four families with ARVD/C and a separate family
segregating arrhythmogenic left ventricular cardiomyop-
athy.7,8 On the basis of impaired cardiac development in
mice with deletions for Pkp2, which encode plakophilin-
2,9 as well as involvement of other desmosomal elements
in ARVD/C, Gerull and colleagues screened 120 probands
with ARVD/C for mutations in PKP2.10 Remarkably, they
found that 32 of these individuals harbored heterozygous
mutations in this gene, for a 27% prevalence among pa-
tients with ARVD/C. We subsequently confirmed high prev-
alence of PKP2 mutations in a separate large cohort of pa-
tients with ARVD/C and reported that those with PKP2 mu-
tations present with arrhythmia earlier than do patients
with ARVD/C who do not have the PKP2 mutation.11
Other genes encoding nondesmosomal proteins have
been implicated in ARVD/C. Mutations in RYR2, which
encodes the cardiac ryanodine receptor, have been de-
scribed in ARVD2, a subtype in which ventricular arrhyth-
mias are particularly effort induced and structural right-
ventricular involvement may be concealed.12,13 In addi-
tion, mutations in RYR2 result in catecholaminergic poly-
morphic ventricular tachycardia.14 Beffagna and colleagues
recently described mutations in the 5′ and 3′ UTRs of the
gene encoding transforming growth factor b3 (TGFB3) in
association with ARVD/C.15 Transient transfection with lu-
ciferase reporter constructs harboring these alterations in
the 5′ and 3′ UTRs suggests increased TGFB3 mRNA abun-
dance, which implicates this cytokine in the pathogenesis
of ARVD/C.
The desmogleins are desmosomal cadherins and, to-
gether with the desmocollins, form the two essential trans-
membrane components of the desmosome.16 Members of
the desmoglein family (DSG1–4) each have four extracel-
lular cadherin domains and a transmembrane domain.
DSG2 is expressed in many tissues, including the myo-
cardium.17 Because of the association between mutations
in three components of the cardiac desmosome and
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A.III-1 3 134GrA R45Q Structural or functional right ventricular abnormality*, histopathologic right ventricular
fibrofatty replacement*, ECG repolarization abnormality†, and diagnostic arrhythmias†
B.II-1 3 143 GrA R48H Structural or functional right ventricular abnormality*, ECG depolarization abnormality*, ECG
repolarization abnormality†, and diagnostic arrhythmias†
B.II-1 8 915 GrA W305X
C.II-1 11 1517 GrA C506Y Structural or functional right ventricular abnormality†, ECG repolarization abnormality†, ECG
depolarization abnormality†, and diagnostic arrhythmias†
D.II-4 15 2431 GrT G811C Family history*, ECG repolarization abnormality†, and structural or functional right ventricular
abnormality†
a An asterisk (*) indicates that a major criterion is filled in the category; a dagger (†) indicates that a minor criterion is filled in the category.
ARVD/C, we analyzed probands with this disorder for mu-
tations in DSG2, which encodes desmoglein-2.
Thirty-three cases of ARVD/C were identified in which
no mutation was present in PKP2 or DSP, genes previously
associated with the classic form of ARVD/C. Written in-
formed consent for genetic analysis was obtained from all
participating individuals after approval of this protocol by
the Johns Hopkins Institutional Review Board. Amplifica-
tion and sequencing of the exonic and adjacent intronic
sequence for the entire DSG2 gene was performed (see
table A1 for primer sequences). Four individuals with
ARVD/C were identified with mutations in DSG2 (table 1
and fig. 1). Each mutation disrupts a highly conserved
amino acid within a functional domain of desmoglein-2
(fig. 2). Each mutation is absent in a control population
of at least 110 ethnically matched individuals (220 control
chromosomes).
Two of these individuals have mutations in the furin-
cleavage site of the desmoglein-2 proprotein. Individual
A.III-1 has a GrA transition at nt 134, which results in
the substitution of a conserved arginine with glutamine
(R45Q). Individual B.II-1 has a GrA transition at nt 143,
which results in the substitution of a conserved arginine
with histidine (R48H). These arginines occur as the first
and fourth amino acids within the R-X-K-R furin-cleavage
motif (fig. 2). ClustalW alignment demonstrates that these
arginines are absolutely conserved in all species and sub-
types of desmoglein, as is the lysine residue.
Newly synthesized desmogleins are initially inactive
because of an NH2-terminal propeptide sequence, which
is then posttranslationally cleaved by subtilisin-like pro-
protein convertases (PCs), to create mature, active pro-
teins. These endoproteases cleave C-terminal to the rec-
ognition motif Arg-X-Lys-Arg (RXKR), which is highly
conserved throughout all cadherin molecules. Coexpres-
sion of the PC furin with human desmoglein-1 or des-
moglein-3 proproteins results in efficient propeptide pro-
cessing.19 Mutation of the tetrapeptide recognition site or
selective inhibition of PCs prevents endoproteolytic pro-
cessing of cadherin propeptides and abrogates their ad-
hesive function.20,21 Therefore, we predict that the R45Q
and R48H mutations abolish furin cleavage of pro-des-
moglein-2, thereby disrupting production of mature, func-
tional protein.
Individual C.II-1 has a mutation (C506Y) in the extra-
cellular anchor (EA) domain, immediately distal to the
fourth extracellular cadherin (EC) domain, which ends at
residue 502. Cysteinertyrosine substitution confers loss
of a sulfur residue that likely participates in disulfide bond-
ing in the nonreducing extracellular environment. This
cysteine is conserved in all species of desmoglein-2 (fig.
2).
Individual D.II-4 has a mutation (G811C) in the intra-
cellular cadherin-typical sequence (ICS) of desmoglein-2.
This region is responsible for binding desmoglein-2 to
plakoglobin, as determined elsewhere by mutagenesis an-
alyses of residues 794–824.22–24 All species and subtypes of
desmogleins have glycine at this position (fig. 2).
In addition to the R48H mutation in the furin-cleavage
domain, individual B.II-1 has a GrA transition at np 915
that results in a premature termination codon (PTC) in
exon 8 (W305X). His 77-year-old unaffected mother (in-
dividual B.I-4) shares the W305X mutation but does not
have the R48H mutation. She underwent screening echo-
cardiography, electrocardiography (ECG), exercise stress
testing, and several 24-h ambulatory Holter monitors. Re-
sults were notable for normal right and left ventricular
size and function, normal ECG depolarization and repo-
larization, atrial fibrillation, and lack of significant ven-
tricular arrhythmias. Because of the absence of any fea-
tures of ARVD/C, endomyocardial biopsy was not per-
formed. The proband’s father (individual B.I-3) died—at
age 74 years from diabetes mellitus and sepsis—prior to
providing a DNA sample or consent for analysis. The fa-
ther’s surviving siblings (individuals B.I-1 and B.I-2) do
not have the R48H mutation. Although the proband may
have inherited this mutation from his father, the mutation
may also be a de novo mutation. RT-PCR analysis, with
use of mRNA derived from the proband’s lymphocytes,
indicates that the R48H mutation occurs on the paternal
allele (fig. 3).
Three of the four probands have single, heterozygous
missense mutations in DSG2. A fourth proband (B.II-1)
has both a missense mutation on one allele of DSG2 and
Figure 1. Pedigrees and chromatograms demonstrating mutations in DSG2 for four probands with ARVD/C. In each pair of chromato-
grams, the top panel is from an unaffected control and the bottom panel is from the affected individual. A, Family A: individual A.III-
1 with heterozygous R45Q (134GrA) mutation. B, Family B: individual B.II-1 with heterozygous R48H (143GrA) mutation and het-
erozygous W305X (915GrA) mutation. C, Family C: individual C.II-1 with heterozygous C506Y (1517GrA) mutation. D, Family D: individual
D.II-4 with heterozygous G811C (2431GrT) mutation. Sequence analyses were performed bidirectionally with an ABI 3730 DNA
Analyzer (Applied Biosystems). Chromatograms were analyzed using Sequencher 4.1 software for mutational analysis and with MacVector
7.2.2 software for ClustalW alignment. For pedigrees, squares represent males, circles represent females, blackened symbols indicate
affected status, unblackened symbols indicate unaffected status, striped symbols indicate subdiagnostic features of ARVD/C, arrowheads
indicate probands, dots indicate mutation carrier(s), and an asterisk (*) indicates that no DNA was available for sequencing.
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Figure 2. Location and conservation of mutated residues. A, Location of mutations along schematic representation of pre-pro-
desmoglein-2. SS p signal peptide sequence; Pro p propeptide; TM p transmembrane domain; IA p intracellular anchor; IPL p
intracellular proline-rich linker; RUD p repeated-unit domains; DTD p desmoglein-specific terminal domain (adapted from the work
of Getsios et al.18). B, ClustalW sequence alignment of human DSG2 to orthologues and to other human desmogleins (DSG1, DSG3, and
DSG4) and desmocollins (DSC2, DSC3,and DSC4). Identical residues are shaded in black; conserved residues are shaded in gray. Mutations
identified in the present study are shown at the top of each alignment. The furin-recognition motif and plakoglobin binding domain
are indicated.
a nonsense mutation on the other. This raises the question
of whether mutations in DSG2 cause disease by a recessive
or dominant mode of inheritance. If inheritance is reces-
sive, the three singly heterozygous probands could harbor
mutations on a second, as-yet-unidentified disease-caus-
ing gene. This could explain why individual B.I-4 shares
the R45Q mutation but has no evidence of ARVD/C on
cardiac magnetic resonance imaging, ECG, Holter moni-
toring, or signal-averaged ECG. Alternatively, these find-
ings could result from dominant inheritance with low
penetrance, as has been reported for other genetic forms
of ARVD/C.25 Complete loss of desmoglein-2 in mice re-
sults in early embryonic lethality.26 The presence of com-
pound heterozygous mutations in individual B.II-1 sug-
gests either partial function or a functional redundancy
in humans that is not present in mice.
Among these probands, none has woolly hair or kera-
toderma. As a child, after receiving penicillin, individual
B.II-1 developed a disseminated cutaneous exanthem with
extensive mucosal involvement, which was diagnosed as
Stevens Johnson syndrome (SJS). Other than a severe post-
operative wound infection, he has had no other cutaneous
diseases. The occurrence of SJS in the proband with com-
pound heterozygosity for mutations in desmoglein-2 sug-
gests that this desmosomal protein may be involved in
the pathogenesis of SJS. Several members of the desmo-
glein family have been associated with other diseases of
the skin. Stanley et al. demonstrated that desmoglein-1 is
the antigen target in pemphigus foliaceus, an autoimmune
disorder affecting skin.27 Similarly, desmoglein-3 and des-
moglein-4 have been identified as antigen targets in pem-
phigus vulgaris.28,29 Mutation in DSG1 has also been de-
scribed in the dominantly inherited skin disease striate
palmoplantar keratoderma type I.30 Mutations in DSG4
result in localized autosomal recessive hypotrichosis.29 Fi-
nally, cleavage of desmoglein-1 by staphylococcal exfoli-
ative toxins has been shown to result in staphylococcal
scalded skin syndrome by facilitating the spread of Staph-
ylococcus aureus under the stratum corneum.31
Results of clinical screening for ARVD/C and DSG2 ge-
netic testing on those family members who consented to
these analyses are available in table A2. Incomplete pen-
etrance is evident, as described in other forms of ARVD/
C.25 The absence of phenotypic manifestations of ARVD/
C in the mother and sister of individual B.II-1, who share
the single W305X mutation, could be due to incomplete
penetrance, or this mutation may be insufficient to re-
sult in ARVD/C in isolation. Because the mutation creates
a PTC, mutant transcripts are predicted to be rapidly de-
graded by the nonsense-mediated mRNA decay (NMD)
pathway.32 This would then suggest that haploinsuffi-
ciency for desmoglein-2 is not the mechanism for disease.
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Figure 3. Compound heterozygous mutations in DSG2 for individ-
ual B.II-1. Total RNA was isolated from Epstein-Barr virus–trans-
formed lymphoblasts from individual B.II-1 (Trizol [Invitrogen];
RNeasy clean-up [Qiagen]), and cDNA was generated by reverse tran-
scription (Superscript III 1st-strand cDNA synthesis kit [Invitro-
gen]). PCR products amplified with primers spanning the proband’s
two mutations were cloned into the pCR2.1 plasmid (TOPO-TA cloning
kit [Invitrogen]), and several individual clones were sequenced using
both M13 forward and reverse primers. Representative chromato-
grams from two clones are displayed, which demonstrate that the
R48H and W305X mutations lie on different alleles.
Even if the mutant transcript escapes NMD, the resulting
truncated protein lacks a transmembrane domain (aa 612–
634) and would likely be secreted extracellularly, which
would prevent a potentially deleterious dominant nega-
tive effect.33 In this model, the phenotypic manifestations
of heterozygous DSG2 mutation carriers would be same as
for those with compound heterozygous mutation, with
one mutation causing a PTC prior to the transmembrane
domain (TM). However, additional individuals harboring
mutations that prevent transmembrane anchoring of des-
moglein-2 are required for definitive conclusions regard-
ing the role of haploinsufficiency.
The mechanism whereby mutations affecting compo-
nents of the cardiac desmosome result in ARVD/C remains
in question. Some have suggested that either a lack of
desmosomal protein or incorporation of mutant protein
will disrupt cell-cell adhesion, predisposing regions of
greatest stretch to fibrofatty degeneration.10,34 Others have
invoked a pathogenic role for viral infection, perhaps
worsened by a mutant cardiac desmosome.35,36 Finally, al-
teration in cytokines such as transforming growth factor
b3 may also contribute to disease pathogenesis.15
In conclusion, we report that mutations in DSG2 con-
tribute to the development of ARVD/C in the absence of
mutations in PKP2 or DSP. This provides further evidence
that disruption of the cardiac desmosome is important
in the pathogenesis of this condition. Since sudden cardiac
death is a prominent manifestation of ARVD/C, recogni-
tion of those at highest risk of developing the condi-
tion may be improved by genetic screening within af-
fected families.
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Exon 1 ACCCAAGGACGTCACGGTCCC CCAAGAGGATTTTCCGAAGCC
Exon 2 AGGAGTCAGTATGGATCCAGG ATTCAGCACCTCGTCATGGAC
Exon 3 TAGACAATGAAGCCTCATAGG CAATGATGCTGCATCTTCCGG
Exon 4 ATCACTTCTTAGGCTTTTGGC
Exon 5 AGGAAAGCAGTTCTGAACTGC
Exon 6 CTAATGTGTTCTAATTGGTTGGACC TTGGCTCACTGCAACTTCTGCC
Exon 7 TTCTGCAAAAGCTCTGACTGC
Exon 8 GAATTTGAACCATAGTGTGACC
Exon 9 AGTTGGACTATTCAGTGCTGC TTTGGGGAACTATAATGCTGG
Exon 10 TGACATGCAGTAAAGAGAGGG CAAAGTGCTGGGATTACAGGC
Exon 11 AAACATCTTCATCAACCTCTGG TTCCAGTGCATCTTTGTGAACG
Exon 12 CAGCAATGAAAGAACATTTGTGG CAGTTGTTTCCCTATTCACCC
Exon 13 GTGAAGACAAGTCCAGGAAGG CAAAGGCACATGAGTGAAATCC
Exon 14 AGCTTATACCTTCCTATGCCC AGTCTCATTTGGATCCAAGGC
Exon 15 TTGTGTTTCCCTGATGGTTCC CTGTAAGGCTCATGAAAAATCAGG
cDNA TGCTTTAACGTTGGAAGTGG TTGATGGGAATGGGTGTAGG
NOTE.—Intronic sense and antisense oligonucleotide primers used for se-
quencing the 15 exons of human DSG2 are shown. Primers used to amplify
the coding region containing both the R48H mutation and the W305X mu-
tation are shown (cDNA). Reference human sequence was obtained from
Ensembl.
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I-1 Not tested 62* Minor Not screened Not screened Not screened Not screened Not screened 0/1
II-1 Not tested 46 Minor None None None None Not screened 0/1
II-2 R45Q 46 Minor None None None None Not screened 0/1
III-1 R45Q 19 Proband Major None Minor Minor major 2/2
III-2 Not tested 16 Minor None None None None Not screened 0/1
Family B:
I-1 None 81 Minor Not screened Not screened Not screened Not screened Not screened NA
I-2 None 80 Minor Not screened Not screened Not screened Not screened Not screened NA
I-3 Not tested 74* Minor None None None None Not screened 0/1
I-4 W305X 77 Minor None None None None Not screened 0/1
II-1 W305X
R48H
42 Proband Major Major Minor Minor Not screened 2/2
II-2 W305X 39 Minor None None None Not screened Not screened 0/1
Family C:
I-1 Not tested 73 Minor None None None None Not screened 0/1
I-2 Not tested 69 Minor None None None None Not screened 0/1
II-1 C506Y 45 Proband None Minor Minor Minor Not screened 0/4
II-2 Not tested 44 Minor None None None None Not screened 0/1
II-3 Not tested 43 Minor Minor None None None Not screened 0/2
II-4 Not tested 39 Minor None None None None Not screened 0/1
II-5 Not tested 39 Minor None None None None Not screened 0/1
Family D:
I-1 None 73 Major None None None Not screened 1/0
I-2 G811C 73 Major Not screened Not screened Not screened Not screened Not screened NA
II-1 Not tested 32* Proband On autopsy Not screened Not screened Not screened On autopsy Autopsyd
II-2 None 45 Major None None None None Normal 1/0
II-3 None 44 Major None None None None Not screened 1/0
II-4 G811C 40 Major Minor None Minor None Not screened 1/2
a An asterisk (*) indicates age at death.
b Minor p satisfies minor criterion in this category; major p satisfies major criterion in this category.
c To establish a diagnosis of ARVD/C, the subject must meet two major criteria, one major and two minor criteria, or four minor criteria in
different categories. NA p not available.
d The diagnosis was established during postmortem autopsy rather than by use of the clinical criteria.
Web Resources
The URLs for data presented herein are as follows:
Ensembl, http://www.ensembl.org/Homo_sapiens/index.html
Johns Hopkins ARVD Program, http://www.arvd.com/
Online Mendelian Inheritance in Man (OMIM): http://www.ncbi
.nlm.nih.gov/Omim/ (for ARVD/C, Naxos syndrome, and Car-
vajal syndrome)
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